Literature DB >> 12691698

Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals.

George Vlad1, Flavia Piazza, Adriana Colovai, Raffaello Cortesini, Fatima Della Pietra, Nicole Suciu-Foca, John S Manavalan.   

Abstract

A characteristic of human immunodeficiency virus infected individuals is an impairment of immune responses, which can result in opportunistic infections. Elevated levels of interleukin-10 (IL-10), produced by virally infected monocytes, are found in the sera of HIV infected individuals. Such elevated levels have been associated with the impaired function of CD4(+) and CD8(+) T cells, and antigen presenting cells (APC), such as monocytes. IL-10 has been reported to upregulate the cell surface expression of the inhibitory receptors ILT3 and ILT4 on monocytes and dendritic cells. This study demonstrates that the decreased antigen presenting ability of monocytes in HIV(+) individuals is in part due to the upregulation of ILT4 on the monocytes caused by the elevated serum IL-10 levels seen in these individuals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691698     DOI: 10.1016/s0198-8859(03)00040-5

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  27 in total

1.  IL-10 enhances promoter activity of ILT4 gene and up-regulates its expression in THP-1 cells.

Authors:  Xiaoli Xu; Ping Zou; Lijuan Chen; Guannan Jin; Hao Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

Review 2.  LILRB receptor-mediated regulation of myeloid cell maturation and function.

Authors:  William van der Touw; Hui-Ming Chen; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Immunol Immunother       Date:  2017-06-21       Impact factor: 6.968

3.  Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres.

Authors:  Jamal S Lewis; Chris Roche; Ying Zhang; Todd M Brusko; Clive H Wasserfall; Mark Atkinson; Michael J Clare-Salzler; Benjamin G Keselowsky
Journal:  J Mater Chem B       Date:  2014-05-07       Impact factor: 6.331

4.  Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation.

Authors:  Urban Svajger; Natasa Obermajer; Matjaz Jeras
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

5.  Inhibition of Th2 adaptive immune responses and pulmonary inflammation by leukocyte Ig-like receptor B4 on dendritic cells.

Authors:  Rebecca G Breslow; Jayanti J Rao; Wei Xing; David I Hong; Nora A Barrett; Howard R Katz
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

6.  Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cells.

Authors:  Juan Wu; Anatolij Horuzsko
Journal:  Hum Immunol       Date:  2009-05       Impact factor: 2.850

7.  Presence of suppressor HIV-specific CD8+ T cells is associated with increased PD-1 expression on effector CD8+ T cells.

Authors:  Mohamed Elrefaei; Chris A R Baker; Norman G Jones; David R Bangsberg; Huyen Cao
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

Review 8.  T-cell exhaustion in HIV infection.

Authors:  Mohamed El-Far; Rabih Halwani; Elias Said; Lydie Trautmann; Mehrnoosh Doroudchi; Loury Janbazian; Simone Fonseca; Julien van Grevenynghe; Bader Yassine-Diab; Rafick-Pierre Sékaly; Elias K Haddad
Journal:  Curr HIV/AIDS Rep       Date:  2008-02       Impact factor: 5.071

Review 9.  Regulation of T-cell immunity by leucocyte immunoglobulin-like receptors: innate immune receptors for self on antigen-presenting cells.

Authors:  Katie J Anderson; Rachel L Allen
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

10.  HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses.

Authors:  Jinghe Huang; James J Goedert; Eric J Sundberg; Thai Duong Hong Cung; Patrick S Burke; Maureen P Martin; Liliana Preiss; Jeffrey Lifson; Mathias Lichterfeld; Mary Carrington; Xu G Yu
Journal:  J Exp Med       Date:  2009-12-14       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.